Is BPC-157 Legal in Tennessee? How to Access It Legally

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

What is BPC-157's federal status?

BPC-157 is a synthetic 15-amino-acid peptide, described as a fragment of a protein first isolated from human gastric juice [1]. No FDA-approved drug contains it, and there is no US Pharmacopeia or National Formulary monograph for it [1]. Websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled for research purposes only and not for human or veterinary use; those are not FDA-approved drugs [1].

Its compounding position has changed. FDA's significant-safety-risk page carried BPC-157 in category 2 from September 2023 until April 22, 2026, then moved it to a 'nominated but withdrawn' table after the nominating groups withdrew; removal was not a finding of safety [5]. It is not in category 1 either, the group FDA generally does not act against compounders for, so that policy does not cover it [3]. FDA's stated concerns stay on the page: possible immunogenicity for certain routes of administration, peptide-related impurities and characterization problems, and too little information to know whether it would harm humans [5]. A July 23, 2026 advisory committee vote favoring the bulks list is advice only and did not add it; FDA staff recommended against listing [8][1].

What does the draft HHS policy say?

HHS filed notice of a draft enforcement-discretion policy on October 28, 2026, scheduled for Federal Register publication on October 30, with public comments open for two weeks after publication [4]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [4].

For BPC-157 those conditions include BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis; a label reading 'This is a compounded drug product. Not for resale.'; a patient-specific prescription; MedWatch reporting of serious adverse events and quality problems; and, for oral forms, documentation of adequate bioavailability [2]. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' [4]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities [4][6]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [6].

What is known about safety and dosing?

There is no FDA-approved dose [1]. FDA's adverse-event search through December 4, 2025 returned three reports, all injectable, and FDA said it cannot tell whether BPC-157 caused them [1]. A 2026 systematic review found three human studies totaling 30 patients, all of poor quality, with certainty of evidence rated very low [9]. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1].